FinscoFinsco

Akebia Therapeutics (US.AKBA)

Capital Allocation Audit · Period: 2012 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.AKBA · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion123.4%↑
ROE-71.8%↓
Cash Conversion-→
D/E Ratio2.20↓
Gross Margin77.9%↓
US.AKBA (Akebia Therapeutics) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   123.4%    ↑
ROE              -71.8%    ↓
Cash Conversion       -    →
D/E Ratio          2.20    ↓
Gross Margin      77.9%    ↓
Key Metrics
US.AKBA (Akebia Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 123.4% ↑
ROE -71.8% ↓
Cash Conversion - →
D/E Ratio 2.20 ↓
Gross Margin 77.9% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies